NCT06470191

A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.

A Multicenter, Randomized, Controlled, Open Phase II/III Clinical Study to Evaluate the Efficacy and Safety of B007 Versus Cyclosporine in the Treatment of Primary Membranous Nephropathy.

• Status: Recruiting
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 216 (estimated)
• Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and safety of B007 in the Treatment of Primary Membranous Nephropathy

Conditions

• Primary Membranous Nephropathy

Interventions

Type	Name	Description
DRUG	B007	B007： Subcutaneous injection was administered on days 1 and 15
DRUG	Cyclosporin Capsules	Cyclosporin Capsules： Orally, 3.5 mg/kg/d；

Timeline

• Start date: 2024-07-30
• Primary completion: 2026-12-31
• Completion: 2026-12-31
• First posted: 2024-06-24
• Last updated: 2025-03-25

Locations

21 sites across 1 country: China